584222

Tetrahydrouridin, CAS-Nr. 18771-50-1, Calbiochem

Potent competitive inhibitor of cytidine deaminase. Also available as a 100 mM solution in H2O.

• Synonym(e): Tetrahydrouridin, CAS-Nr. 18771-50-1, Calbiochem
• Empirische Formel (Hill-System): C₉H₁₆N₂O₆
• CAS-Nummer: 18771-50-1
• Molekulargewicht: 248.23
• UNSPSC-Code: 12352208
• NACRES: NA.51

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥90% (TLC)
• Form: solid
• Hersteller/Markenname: Calbiochem^®
• Lagerbedingungen: OK to freeze; desiccated (hygroscopic); protect from light
• Farbe: white to off-white
• Löslichkeit: water: 200 mg/mL
• Versandbedingung: wet ice
• Lagertemp.: −20°C
• InChI: 1S/C9H16N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h4-8,12-15H,1-3H2,(H,10,16)/t4-,5?,6-,7-,8-/m1/s1
• InChIKey: UCKYOOZPSJFJIZ-XVKVHKPRSA-N

Beschreibung

Allgemeine Beschreibung

Ein potenter kompetitiver Inhibitor der Cytidindesaminase. Auch als 100-mM-Lösung in H₂O (Kat.-Nr. 584223) erhältlich.

Ein potenter kompetitiver Inhibitor der Cytidindesaminase. Wird in Kombination mit Cytosinarabinosid (Ara-C) verwendet, um die leukämie- und tumorhemmende Wirkung von Ara-C in In-vitro-Studien zu bewerten.

Anwendung

• Oncotherapy resistance explained by Darwinian and Lamarckian models.: This research explores the mechanisms of oncotherapy resistance, combining Darwinian and Lamarckian models to provide a comprehensive understanding. The study highlights the role of Tetrahydrouridine in modulating therapy resistance pathways in cancer treatment (Saunthararajah et al., 2024).


• Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.: This study investigates the potential of using Tetrahydrouridine in non-cytotoxic therapies for small cell lung cancers, focusing on neuroendocrine lineage commitment and its implications for treatment efficacy (Biswas et al., 2023).


• In Vitro Interaction of Tetrahydrouridine with Key Human Nucleoside Transporters.: This study explores how Tetrahydrouridine interacts with human nucleoside transporters, shedding light on its mechanisms of action and potential as a therapeutic agent in biochemistry and pharmacology (Säll et al., 2023).


• Mycoplasma infection of cancer cells enhances anti-tumor effect of oxidized methylcytidines.: This research investigates how mycoplasma infection enhances the anti-tumor effects of oxidized methylcytidines, with Tetrahydrouridine playing a crucial role in the observed therapeutic outcomes (Pang et al., 2023).

Verpackung

Verpackt unter inertem Gas

Warnhinweis

Toxizität: Standard-Handhabung (A)

Rekonstituierung

Nach der Rekonstitution in Aliquote aufteilen, mit inertem Gas spülen und einfrieren (-20 °C). Wässrige Stammlösungen (bei neutralem oder basischem pH-Wert) sind bei -20 °C bis zu 3 Monate haltbar.

Sonstige Hinweise

Yusa, K., et al. 1995. Biochem. Biophys. Res. Commun. 206, 486.
Bouffard, D.Y., et al. 1993. Biochem Pharmacol.45, 1857.
Laliberte, J., et al. 1992. Cancer Chemotherapie. Pharmacol.30, 7.
Riva, C., et al. 1992. Chemotherapy38, 358.
Yusa, K., et al. 1992. J. Biol. Chem. 267, 16848.
Hanze, A.R., et al. 1967. J. Am. Chem. Soc.89, 6720.

Rechtliche Hinweise

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable